⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538982 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL18398541 | 0.60 | — | — | |
| SCHEMBL21247932 | 0.60 | — | — | |
| SCHEMBL935394 | 0.58 | — | — | |
| SCHEMBL93489 | 0.58 | — | — | |
| SCHEMBL3083556 | 0.58 | — | — | |
| SCHEMBL28642721 | 0.57 | — | — | |
| SCHEMBL249488 | 0.55 | — | — | |
| SCHEMBL28679176 | 0.55 | — | — | |
| SCHEMBL20787073 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-02-28 | — | — | US | claimed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-4341262-A1 | AXL INHIBITOR COMPOUNDS | Arcus Biosciences, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022246179-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| CN-109963848-B | Substituted N- (3-fluoropropyl) -pyrrolidine compounds, preparation thereof and therapeutic use thereof | 赛诺菲 | 2022-07-05 | — | — | CN | disclosed |
| CN-109422737-B | Imidazolone androgen receptor antagonist, preparation method and application thereof | 上海时莱生物技术有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020247679-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| CN-111825656-A | Inhibitors of protein arginine methyltransferase 5(PRMT5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3085696-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2014179492-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE | GILEAD SCIENCES, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| CN-103857659-A | Fused heterocyclic compounds as modulators of ion channels | GILEAD SCIENCES INC | 2014-06-11 | — | — | CN | disclosed |